Evaluating PCSK9 Inhibitor with Statin Treatment for Adults Aged 18 to 80
with Asymptomatic Intracranial Artery Narrowing to Reduce Stroke Risk
Led by Peking Union Medical College Hospital · Updated on 2026-06-12
300
Participants Needed
19
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying asymptomatic intracranial atherosclerosis ICAS, a condition where arteries in the brain narrow without causing symptoms but increase the risk of stroke and cognitive decline. This trial evaluates the effects and safety of combining a PCSK9 inhibitor drug with statin therapy compared to statin therapy alone in reversing this artery narrowing. The study is a multicenter, open-label, randomized controlled trial with blinded assessment of results.
Participants will be randomly assigned to one of two groups one receiving Recaticimab a PCSK9 inhibitor every 12 weeks alongside daily statin medication rosuvastatin or atorvastatin, and the other receiving statin therapy alone. Ezetimibe may be added based on cholesterol levels. Treatments last for 24 weeks. Recaticimab is designed with a modification to extend its activity, allowing dosing every 12 weeks. The primary goal is to measure changes in artery plaque using high-resolution MRI.
During the study, participants will undergo MRI scans to assess plaque changes, blood tests to measure cholesterol and brain injury markers, and clinical evaluations for stroke or transient ischemic attacks. Additional outcomes include cardiovascular events and cholesterol management success. After the 24-week treatment, participants will be followed for over a year via clinical or phone visits to monitor long-term effects. The study aims to enroll 300 participants and includes safety monitoring by an independent board.
CONDITIONS
Brief Title
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Research Team
W
Weihai Xu, MD
Y
Yiyang Liu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Asymptomatic intracranial artery stenosis (50%-99%) confirmed by angiography in specified brain arteries
Atherosclerosis as the cause of artery narrowing confirmed by high-resolution MRI
No previous ischemic stroke or transient ischemic attack
Baseline low-density lipoprotein cholesterol (LDL-C) of at least 1.8 mmol/L
Signed informed consent
You will not qualify if you...
Non-atherosclerotic causes of intracranial artery narrowing such as arterial dissection, moya moya disease, vasculitis, infections, or other specified conditions
Significant extracranial vessel stenosis adjacent to the target artery
Prior or planned endovascular intervention of the target lesion within 6 months
Intracranial hemorrhage within 90 days before enrollment
Presence of intracranial tumors, aneurysms, or arteriovenous malformations needing intervention
Major surgery within 30 days before or planned within 6 months after enrollment
Certain heart conditions including mitral stenosis, mechanical valves, recent myocardial infarction, atrial fibrillation, or low heart function
Severe liver or kidney dysfunction as defined by specific lab values
Active bleeding disorders or coagulopathy
Systemic autoimmune diseases
Dementia or psychiatric conditions that impair adherence
Contraindications to MRI
Uncontrolled high blood pressure during screening
Prior use of PCSK9 inhibitors
Known statin intolerance or allergy
Pregnancy, lactation, or planning pregnancy
Participation in another clinical study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 24 weeks
Participants receive either Recaticimab combined with statin therapy or statin therapy alone for 24 weeks.
Follow-up
Duration - More than 1 year
Participants are followed for more than one year through clinical or telephone visits to monitor long-term effects after treatment ends.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating the Safety and Effectiveness of the NOVA Drug-Eluting Stent for Treating Intracranial Artery Narrowing in Adults
Atherosclerotic Plaque Imaging Project to Identify Vulnerable Plaques Using Imaging and Biological Markers
Study of Short-Term High-Dose Rosuvastatin Effects on Coronary Plaque Using Advanced CT Imaging
in Statin-Naive Adults with Stable Chest Pain
Aged 40-75 Years
Study on Cognitive Decline and Treatment Effects in Adults with Severe Intracranial Artery Narrowing and Minor Stroke or TIA
Genetic Testing to Guide Medication Choice Versus Standard Clopidogrel Treatment in Adults With Symptomatic Brain Artery Narrowing After Stroke
Fish Oil and Metformin Treatment to Improve Heart Health and Metabolism in Women with PCOS
A 12-Month Study on Cardiovascular Risk and Insulin-Glucose Control
Study of Gut Microbiota and Outcomes in Adults Aged 30 to 80 with Intracranial Artery Narrowing
High-Resolution Magnetic Resonance Imaging Study of Intracranial Atherosclerotic Plaques in Ischemic Stroke Patients in China
Screening for Intracranial Atherosclerosis Using Retinal Imaging Features
and Artificial Intelligence
Study on Improving Blood Lipid Management Using Statins and PCSK9 Inhibitors to Reduce Stroke in Patients With Symptomatic Intracranial Artery Narrowing
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial.
The prevalence and prognosis of asymptomatic intracranial atherosclerosis in a community-based population: Results based on high-resolution magnetic resonance imaging.